We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Tests Improved for Detection of Helicobacter Pylori Antigen

By LabMedica International staff writers
Posted on 28 Oct 2009
Tests for the of Helicobacter pylori antigen in stool samples have been improved. More...
These tests can be used for the diagnosis and management of active H. pylori infection.

Employing a combination of amplification technology and monoclonal antibodies, two noninvasive tests can be performed using a patient stool sample. They detect H. pylori antigen with a high degree of accuracy and can be used to diagnose current infection in both adult and pediatric patients. Unlike serology methods, these stool antigen tests can be used to detect active infection and to confirm the eradication of H. pylori following antibiotic therapy.

A rapid immunochromatographic membrane-based assay provides reliable results in just 15 minutes, without the need for special equipment. Called Rapid Hp StAR, the method is suitable for small volume testing in the laboratory or for near patient testing in gastroenterology clinics and doctors offices. This makes it convenient for monitoring the efficacy of antimicrobial treatment without the need for return hospital visits.

The second test, IDEIA Hp StAR, is a sensitive and specific enzyme immunoassay. The test is easy to perform using standard equipment, allowing the "test and treat” policy recommended by the European Helicobacter Study Group (EHSG) to be implemented in routine laboratories. It is suitable for both manual and automated testing and has demonstrated good performance when compared to the urea breath test and alternative enzyme immunoassays.

The two tests are produced by Oxoid (Basingstoke, UK), a microbiology company whose products are used in laboratories to help diagnose infectious diseases. Laura Ward, marketing manager, Oxoid commented, "The Hp StAR tests provide cost effective, noninvasive alternatives to the more invasive methods offered by many hospitals. They involve minimal discomfort for the patient, making them particularly suitable for pediatric use. Furthermore, the ability to detect active infections also helps to avoid the unnecessary administration of antibiotics."

Oxoid is part of Thermo Fisher Scientific Inc. (Waltham MA, USA). Thermo Scientific offers analytical instruments as well as laboratory equipment, software, services, consumables, and reagents to enable integrated laboratory workflow solutions. Fisher Scientific has a portfolio of laboratory equipment, chemicals, supplies, and services used in healthcare, scientific research, safety, and education.

Related Links:

Oxoid
Thermo Fisher Scientific Inc.




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.